+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05243797

Phase 3 Randomized Study Comparing Teclistamab With Lenalidomide Alone or Combined as Maintenance Therapy After Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

Led by European Myeloma Network B.V. · Updated on 2026-10-07

1594

Participants Needed

212

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of teclistamab, both alone and in combination with lenalidomide, compared to lenalidomide alone as maintenance therapy in participants newly diagnosed with multiple myeloma following autologous stem cell transplant. This Phase 3, multicenter, randomized, open-label study aims to understand the benefits of these treatments in maintaining disease control after initial therapy. The study is sponsored by the European Myeloma Network B.V. and focuses on improving progression-free survival and disease response in this patient population. Participants are randomly assigned to one of three groups teclistamab combined with lenalidomide, lenalidomide alone, or teclistamab alone. Teclistamab is given as a subcutaneous injection, while lenalidomide is taken orally. The study treatment continues as maintenance therapy after the transplant. The trial compares the effects of these regimens over a long follow-up period, with assessments planned for up to 8 years. During the study, participants undergo regular evaluations including clinical exams, laboratory tests, and quality of life questionnaires such as the EORTC QLQ-C30 and MySIm-Q. Researchers monitor disease progression, survival, and treatment-related symptoms using patient-reported outcomes and clinical measures. The primary outcomes are progression-free survival from randomization and the rate of minimal residual disease-negative complete response at 12 months. Safety and quality of life are also closely followed throughout the study duration.

CONDITIONS

Brief Title

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Research Team

C

Christine Witty

S

Sabrin Tahri

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here